Patents by Inventor Arash Raoufinia

Arash Raoufinia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUSTAINED RELEASE ORAL SOLID PREPARATION
    Publication number: 20150037424
    Abstract: Provided is a sustained release oral solid preparation comprising aripiprazole or a salt thereof as an active ingredient described below, and a method for producing the sustained release oral solid preparation.
    Type: Application
    Filed: March 6, 2013
    Publication date: February 5, 2015
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Robert A. Forbes, Suresh Mallikaarjun, Arash Raoufinia, Ron Casey, Junichi Jinno, Hiroyuki Nagao, Donald Diehl, Erik Pecorelli, Anthony Carpanzano
  • Once daily formulations of tetracyclines
    Patent number: 8709478
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: April 29, 2014
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • ONCE DAILY FORMULATIONS OF TETRACYCLINES
    Publication number: 20140072626
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Application
    Filed: June 18, 2013
    Publication date: March 13, 2014
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Once daily formulations of tetracyclines
    Patent number: 8470364
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: June 25, 2013
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Once daily formulations of tetracyclines
    Patent number: 8394406
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: March 12, 2013
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Once daily formulations of tetracyclines
    Patent number: 8394405
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: March 12, 2013
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Once daily formulations of tetracyclines
    Patent number: 8206740
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: June 26, 2012
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Once daily formulations of tetracyclines
    Publication number: 20110319368
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Application
    Filed: December 17, 2010
    Publication date: December 29, 2011
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Once daily formulations of tetracyclines
    Publication number: 20110294759
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Application
    Filed: December 17, 2010
    Publication date: December 1, 2011
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Once daily formulations of tetracyclines
    Publication number: 20110288056
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Application
    Filed: December 17, 2010
    Publication date: November 24, 2011
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • PHARMACEUTICAL COMPOSITION FOR ONCE A DAY ADMINISTRATION OF TROSPIUM CHLORIDE
    Publication number: 20100221356
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw KIDANE, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • PHARMACEUTICAL COMPOSITION FOR THE ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE
    Publication number: 20100221352
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw KIDANE, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Pharmaceutical Composition Comprising Trospium Chloride for Once-A-Day Administration
    Publication number: 20100222375
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw KIDANE, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Pharmaceutical Composition For Once-A-Day Administration of Trospium Chloride
    Publication number: 20100221353
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw KIDANE, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • PHARMACEUTICAL COMPOSITION FOR ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE
    Publication number: 20100221355
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw KIDANE, Henry H. FLANNER, Padmanabh BHATT, Arash RAOUFINIA
  • PHARMACEUTICAL COMPOSITION FOR ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE
    Publication number: 20100221354
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily dosage forms of trospium
    Patent number: 7781448
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: August 24, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Trospium chloride treatment method
    Patent number: 7781449
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: August 24, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily dosage forms of trospium
    Patent number: 7763635
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: July 27, 2010
    Assignee: Supermus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Method of treating bladder dysfunction with once-a-day trospium salt formulation
    Patent number: 7759359
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: July 20, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia